Stryker Corp. Announces Launch of Next-Generation InThrill Thrombectomy System
PORTAGE, Mich., July 29, 2025 — Stryker Corporation (NYSE: SYK), a leading health care equipment and supplies company, has announced the launch of the next-generation InThrill Thrombectomy System through its division, Inari Medical. This innovative system is designed to address arteriovenous access and small vessel thrombus cases, marking a significant advancement in medical technology.
The new InThrill Thrombectomy System is the first and only purpose-built solution for small vessel and arteriovenous (AV) access thrombectomy. It features an 8 French over-the-wire system that includes the InThrill thrombectomy catheter and sheath. The system is optimized for fast, full luminal clot removal, offering unmatched efficiency and improved patient outcomes.
Key enhancements of the InThrill system include increased radial force for better luminal wall apposition, an offset single open mouth for optimized clot capture, internal struts for even clot distribution, and improved ergonomic design. These features collectively enhance the system’s performance and usability.
The first commercial use of the InThrill system was successfully performed on May 19, 2025, at the UPMC health care system by Dr. Joshua Pinter and Dr. Anish Ghodadra. The doctors noted significant improvements in thrombectomy procedures, highlighting the system’s potential to become the standard in the field.
Stryker’s Financial Overview
As of July 29, 2025, Stryker’s stock closed at $400.41 on the New York Stock Exchange. The company’s market capitalization stands at $151.59 billion, with a price-to-earnings ratio of 53.116. Over the past year, Stryker’s stock has fluctuated between a high of $406.19 on January 27, 2025, and a low of $314.93 on August 4, 2024.
Analysts have identified Stryker’s orthopedics segment, particularly its robot-assisted surgeries, as a major growth driver. This segment is expected to double over the next five years, with robots accounting for approximately 45% of the orthopedics business. Analysts have set a price target of $429.76 for Stryker’s stock.
Market Outlook
Despite concerns about tariff overhang, there is anticipation around Stryker’s Q2 earnings, with expectations of strong growth reflecting the company’s strategic advancements and market positioning. The launch of the InThrill Thrombectomy System is expected to bolster Stryker’s portfolio, reinforcing its leadership in medical technologies.
Stryker continues to innovate and expand its offerings in the health care sector, maintaining its commitment to improving patient care through advanced medical solutions.